News
AVEO
6.12
-4.38%
-0.28
Strong week for AVEO Pharmaceuticals (NASDAQ:AVEO) shareholders doesn't alleviate pain of five-year loss
This week we saw the AVEO Pharmaceuticals, Inc. ( NASDAQ:AVEO ) share price climb by 20%. But will that heal all the...
Simply Wall St. · 06/22 14:32
BRIEF-Aveo Oncology Announces Clinical Trial Collaboration And Supply Agreement With Eli Lilly And Co
reuters.com · 06/22 13:23
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC
- This agreement follows AVEO’s entry into a similar agreement with Merck KGaA, Darmstadt, Germany to provide cetuximab clinical drug supply outside of the U.S. and Canada - - AVEO Currently Manufacturing Ficlatuzumab Clinical Supply; Potential Phase 3 Reg...
GlobeNewswire · 06/22 12:00
BRIEF-Aveo Oncology Announces Updated Nccn Clinical Practice Guidelines Elevate Fotivda (Tivozanib) To Category 1 Treatment For Relapsed Or Refractory Advanced (R/R) Renal Cell Carcinoma (Rcc) Patients
reuters.com · 06/21 13:53
AVEO Oncology Announces Updated NCCN Clinical Practice Guidelines Elevate FOTIVDA To Category 1 Treatment For Relapsed Or Refractory Advanced Renal Cell Carcinoma Patients
AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the National Comprehensive Cancer Network® (NCCN) has elevated FOTIVDA® (tivozanib) to Category 1
Benzinga · 06/21 12:05
AVEO Oncology Announces Updated NCCN Clinical Practice Guidelines Elevate FOTIVDA® (tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced (R/R) Renal Cell Carcinoma (RCC) Patients
BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the National Comprehensive Cancer Network® (NCCN) has elevated FOTIVDA® (tivozanib) to Category 1 status...
GlobeNewswire · 06/21 12:00
AVEO Oncology Presents Three Posters for Tivozanib at the 2022 ASCO Annual Meeting
Exploratory long-term OS analyses of TIVO-3 continue to trend in favor of tivozanib, patients with PFS at 1 year demonstrated a 55% reduction in risk of death on tivozanib as compared to sorafenib Latest analysis of Phase 2 study show tivozanib demonstrate...
GlobeNewswire · 06/06 12:00
Looking Into AVEO Pharmaceuticals's Return On Capital Employed
AVEO Pharmaceuticals (NASDAQ:AVEO) brought in sales totaling $20.92 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 40.58%, resulting in a loss of $10.20 million.
Benzinga · 05/26 13:49
AVEO Oncology Announces Participation at the H.C. Wainwright Global Investment Conference
BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright Glo...
GlobeNewswire · 05/18 12:30
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
It's been a mediocre week for AVEO Pharmaceuticals, Inc. ( NASDAQ:AVEO ) shareholders, with the stock dropping 15% to...
Simply Wall St. · 05/08 12:33
Is AVEO Pharmaceuticals (NASDAQ:AVEO) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Simply Wall St. · 05/06 19:57
Recap: AVEO Pharmaceuticals Q1 Earnings
  AVEO Pharmaceuticals (NASDAQ:AVEO) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/05 13:22
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/05 12:43
AVEO Pharmaceuticals (AVEO) Reports Q1 Loss, Misses Revenue Estimates
AVEO (AVEO) delivered earnings and revenue surprises of -15.38% and 1.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 12:35
AVEO Pharmaceuticals Q1 EPS $(0.30) Misses $(0.25) Estimate, Sales $20.92M Beat $20.65M Estimate
AVEO Pharmaceuticals (NASDAQ:AVEO) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.25) by 20 percent. This is a 62.96 percent increase over losses of $(0.81) per share
Benzinga · 05/05 11:15
AVEO Pharmaceuticals GAAP EPS of -$0.30, revenue of $20.9M
AVEO Pharmaceuticals press release (NASDAQ:AVEO): Q1 GAAP EPS of -$0.30. Revenue of $20.9M. FY22 FOTIVDA U.S. net product revenues expectations of between $100.0M and $110.0M to be achieved.
Seekingalpha · 05/05 11:09
-- Earnings Flash (AVEO) AVEO PHARMACEUTICALS Reports Q1 Revenue $20.9M, vs. Street Est of $20.8M
MT Newswires · 05/05 07:01
Earnings Preview: AVEO Pharmaceuticals
AVEO Pharmaceuticals (NASDAQ:AVEO) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that AVEO Pharmaceuticals will report an earnings per share (EPS) ...
Benzinga · 05/04 14:21
AVEO Pharmaceuticals Earnings Conference Call Is Coming Up, Here's What You Need To Know
  AVEO Pharmaceuticals (NASDAQ:AVEO) will host a conference call at 08:30 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.
Benzinga · 05/04 09:54
AVEO Oncology to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022
BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022. AVEO’s management te...
GlobeNewswire · 04/28 12:30
More
Webull provides a variety of real-time AVEO stock news. You can receive the latest news about Aveo Pharma through multiple platforms. This information may help you make smarter investment decisions.
About AVEO
AVEO Pharmaceuticals, Inc. is an oncology biopharmaceutical company that is focused on delivering medicines for patients with cancer. The Company’s products and development program include FOTIVDA, ficlatuzumab, AV-380 and AV-203 AV-203. It develops FOTIVDA in immuno-oncology combinations in refractory renal cell carcinoma (RCC) and other indications and has several other investigational programs in clinical development. The Company markets FOTIVDA (tivozanib) in the United States for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. The Company’s pipeline of product candidates includes ficlatuzumab, a potent humanized immunoglobulin G1 monoclonalantibody that targets hepatocyte growth factor (HGF). It is also conducting a randomized Phase II confirmatory study of ficlatuzumab for the potential treatment of HNSCC.